Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05457465
PHASE2

Assessing the Impact of Cannabidiol for Anxiety and Depression in Bipolar Disorder

Sponsor: Mclean Hospital

View on ClinicalTrials.gov

Summary

Preliminary data have suggested that cannabidiol (CBD) may have a number of clinical benefits, including anti-anxiety and antidepressant properties. This study is a pilot open-label clinical trial assessing a custom-formulated high-CBD product over the course of 4 weeks in patients with bipolar disorder who experience anxiety.

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

25

Start Date

2023-06-01

Completion Date

2026-12

Last Updated

2026-03-30

Healthy Volunteers

No

Interventions

DRUG

Cannabidiol

Custom formulation of a hemp-derived, high-CBD product that contains no THC.

Locations (1)

McLean Hospital

Belmont, Massachusetts, United States